Lixte Biotechnology Holdings Announces Extension of Its Cooperative Research and Development Agreement With The National Institu
25 Giugno 2008 - 5:36PM
PR Newswire (US)
EAST SETAUKET, N.Y., June 25 /PRNewswire-FirstCall/ -- Lixte
Biotechnology Holdings (OTC:LIXT) (BULLETIN BOARD: LIXT) announced
today that the National Institute of Neurological Disorders and
Stroke (NINDS), National Institutes of Health (NIH) and Lixte
Biotechnology Holdings, Inc. extended their Cooperative Research
and Development Agreement (CRADA) to develop drugs for the
treatment of brain cancers. The CRADA, initiated in March 2006 was
extended through September 2009. Dr. John S. Kovach, President and
CEO of Lixte, said, "The scientific interaction with the research
team at the Molecular Pathogenesis Unit (MPU), Surgical Neurology
Branch, (SNB), NINDS, has been highly productive and is a good
example of how government and private sector scientific
organizations may accelerate the drug development process. A novel
biomarker of glioblastoma multiforme, the most common and
aggressive brain tumor of adults, discovered at the MPU, SNB led to
insights into potential vulnerability of this devastating cancer to
pharmacologic attack. Based on these insights, Lixte synthesized
two different types of anti-cancer drugs that target the biomarker.
In less than two years, working with the MPU, SNB under the CRADA,
Lixte has identified lead compounds of both types, which inhibit
glioblastoma multiforme in animal models. These novel compounds are
now undergoing pre- clinical evaluation of their pharmacologic
characteristics, the first step in the process of preparing an
Investigational Drug Application (IND) to the FDA for clinical
evaluation." About Lixte Biotechnology Holdings, Inc.: Lixte
Biotechnology Holdings, Inc. is a cancer therapeutics and
diagnostics company. Founded as a biomarker-diagnostics company in
2005, Lixte develops new chemotherapy drugs targeting molecular
abnormalities of common human cancers. About the National Institute
of Neurological Disorders and Stroke (NINDS), (NIH): NINDS
(http://www.ninds.nih.gov/) is a component of the National
Institutes of Health (NIH), and is the nation's primary supporter
of biomedical research on the brain and nervous system. The
National Institutes of Health (NIH) - The Nation's Medical Research
Agency - includes 27 Institutes and Centers and is a component of
the U.S. Department of Health and Human Services. It is the primary
federal agency for conducting and supporting basic, clinical and
translational medical research, and it investigates the causes,
treatments, and cures for both common and rare diseases. For more
information about NIH and its programs, visit http://www.nih.gov/.
Forward-Looking Statements This announcement contains certain
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, and Section 21E of the Securities Exchange
Act of 1934. For example, statements regarding the Company's
financial position, business strategy and other plans and
objectives for future operations, and assumptions and predictions
about future product demand, supply, manufacturing, costs,
marketing and pricing factors are all forward-looking statements.
These statements are generally accompanied by words such as
"intend," anticipate," "believe," "estimate," "potential(ly),"
"continue," "forecast," "predict," "plan," "may," "will," "could,"
"would," "should," "expect" or the negative of such terms or other
comparable terminology. The Company believes that the assumptions
and expectations reflected in such forward-looking statements are
reasonable, based on information available to it on the date
hereof, but the Company cannot provide assurances that these
assumptions and expectations will prove to have been correct or
that the Company will take any action that the Company may
presently be planning. However, these forward-looking statements
are inherently subject to known and unknown risks and
uncertainties. Actual results or experience may differ materially
from those expected or anticipated in the forward-looking
statements. Factors that could cause or contribute to such
differences include, but are not limited to, regulatory policies,
available cash, research results, competition from other similar
businesses, and market and general economic factors. This
discussion should be read in conjunction with the condensed
consolidated financial statements and notes thereto included on
Form 10-QSB for the quarter ending March 31, 2008. Please see our
Website: http://www.lixte.com/ For Investor Information, please
contact: Frank Benedetto Mirador Consulting, Inc. 561-989-3600
DATASOURCE: Lixte Biotechnology Holdings, Inc. CONTACT: Investor
Information, Frank Benedetto, Mirador Consulting, Inc.
+1-561-989-3600 Web site: http://www.lixte.com/
Copyright